Systemic Targeted Therapies in Patients with Relapsed/Refractory Advanced Stage Cutaneous T-cell Lymphoma: A Real-world Single-centre Case Series
Acta Dermato-Venereologica · 2025
DOI: 10.2340/actadv.v105.40952 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Dermato-Venereologica, 2025. Verfasst von Signe Hedebo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology Aarhus University Hospital, Aarhus, Denmark; Aarhus University, Aarhus, Denmark. siheha@rm.dk. Hauptthemen laut MEDLINE: Skin Neoplasms, Antibodies, Monoclonal, Humanized, Alemtuzumab, Brentuximab Vedotin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Cutaneous T-cell lymphomas are a heterogeneous group of non-Hodgkin lymphomas. Early stages are often controlled with skin-directed therapy, such as topical corticosteroids, topical chlormethine gel, or UV therapy, whereas advanced stages often warrant a more aggressive approach with systemic antibody targeted therapy including mogamulizumab, brentuximab vedotin, or alemtuzumab. A retrospective cohort case series of 27 patients from Aarhus University Hospital, Denmark is presented, evaluating real-world outcomes of patients with cutaneous T-cell lymphomas treated with intravenous systemic targeted therapies from 2013 to 2023. The median age was 72 and the majority had Sézary syndrome or mycosis fungoides. All patients had relapsed/refractory advanced stage cutaneous T-cell lymphoma. Six patients received mogamulizumab, 12 patients received brentuximab vedotin, and 15 patients received alemtuzumab. Six patients received more than 1 of the systemic targeted treatments. Overall response rates were 78% for mogamulizumab, 65% for brentuximab vedotin, and 61% for alemtuzumab. Median time to progression was 2.5, 4, and 11 months, respectively. In conclusion, this paper offers a unique perspective on the complexities of clinical practice when managing advanced-stage cutaneous T-cell lymphomas and demonstrates the effectiveness of the therapies described, with particular emphasis on the promising results observed with alemtuzumab administered in a low-dose protocol.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Venereology Aarhus University Hospital, Aarhus, Denmark; Aarhus University, Aarhus, Denmark. siheha@rm.dk.
- Aarhus University, Aarhus, Denmark; Department of Hematology Aarhus University Hospital, Aarhus, Denmark.
- Aarhus University, Aarhus, Denmark.
- Department of Dermatology and Venereology Aarhus University Hospital, Aarhus, Denmark; Aarhus University, Aarhus, Denmark.
- Department of Dermatology and Venereology Aarhus University Hospital, Aarhus, Denmark; Aarhus University, Aarhus, Denmark; MC2 Therapeutics, Hoersholm, Denmark.
- 1Department of Dermatology and Venereology Aarhus University Hospital, Aarhus, Denmark; Aarhus University, Aarhus, Denmark.
ORCID-Profile: Signe Hedebo, Martin B Pedersen, Claus Johansen, Francesco D'Amore, Lars Iversen
Zitieren
APA
Hedebo, S., Pedersen, M. B., Lindahl, L. M., Drjlevic-Nielsen, A., Johansen, C., D'Amore, F., Iversen, L., & Bech, R. (2025). Systemic Targeted Therapies in Patients with Relapsed/Refractory Advanced Stage Cutaneous T-cell Lymphoma: A Real-world Single-centre Case Series. Acta Dermato-Venereologica. https://doi.org/10.2340/actadv.v105.40952
Vancouver
Hedebo S, Pedersen MB, Lindahl LM, Drjlevic-Nielsen A, Johansen C, D'Amore F, et al. Systemic Targeted Therapies in Patients with Relapsed/Refractory Advanced Stage Cutaneous T-cell Lymphoma: A Real-world Single-centre Case Series. Acta Dermato-Venereologica. 2025. doi:10.2340/actadv.v105.40952
BibTeX
@article{Hedebo2025,
author = {Hedebo, Signe and Pedersen, Martin B and Lindahl, Lise M and Drjlevic-Nielsen, Aska and Johansen, Claus and D'Amore, Francesco and Iversen, Lars and Bech, Rikke},
title = {Systemic Targeted Therapies in Patients with Relapsed/Refractory Advanced Stage Cutaneous T-cell Lymphoma: A Real-world Single-centre Case Series},
journal = {Acta Dermato-Venereologica},
year = {2025},
doi = {10.2340/actadv.v105.40952}
}
EUVIMED